1Kawda K. A multicenter and open label clinical trial of zoledronic acid 4mg in patients with hypercalcemia of malignancy[J], Jpn J Clin Onco1,2005,35 ( 1 ) :28-33.
2Neville-Webbe HL. The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia [ J ]. Palliat Med, 2003,17(6) :539-553.
2[3]Coleman RE, Purohit OP. Osteoclast inhibition for the treatment of bone metastases[J]. Cancer Treat Rev, 1993, 19(1): 79 ～ 103
3[4]Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lyric bone lesion: a randomized, placebo-controlled trial.Protocol 18 Aredia Breast Cancer Study Group [J].J Clin Oncol,1999, 17(3): 846～854
4[5]Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats [J]. Cancer Res,2002, 62(22): 6538～6544
5[6]Boissier S, Magnetto S, Fraappart L, et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices [J]. Cancer Res, 1997,57(18): 3890～3894
6[7]Lipton A, Berenson JR. Bisphosphonate treatment of Lyric bone metastases[J]. Drugs Aging, 1999, 14(4): 241～246
7Neville-Webbe H,Coleman RE,et al.The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia[J].Palliat Med,2003,17(6):539-553.
8Matsumoto S,Kimura S,Segawa H,et al.Efficacy of the third-generation bisphosphonate,zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines[J].Lung Cancer,2005,47(1):31-39.
9Chen T,Berenson J,Vescio R,et al.Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases[J].J Clin Pharmacol,2002,42(11):1228-1236.
10Rosen LS,Gordon D,Tchekmedyian NS,et al.Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non-small cell lung carcinoma and other solid tumors:a randomized,Phase III,double-blind,placebo-controlled trial[J].Cancer,2004,100 (12):2613-2621.
4F Fulfaro,A Casuscio,C Ticozzi,et al.The rde of bisphosphonates in zhe treatment of painful metastatic bone disease:a review of phaseⅢtrials.pain,1998,(78):157-169.
5Goldberg PG,Sundquist S,Nilvebrant L.Comparison of the invitro and vivo profiles of tolterodine with those if subtypeselective mus2 carinic receptors anagonists.fur Ipharmacol.1998,349(2):285-292.
8Saad F, Gleason D, Murray R, et al A randomized, placebo-con- trolled trial of zoledronic acid in patients with hormone-refactory metastatic prostate carcinoma. J Natl Cancerlnst, 2002,94 ( 19 ) : 458-1468.
9Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors. J Clinoneol, 2003, 21 ( 16 ) : 3150-3157.
